Spots Global Cancer Trial Database for advanced hematologic malignancies
Every month we try and update this database with for advanced hematologic malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer | NCT04991129 | Advanced Hemato... Advanced Solid ... | WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 | 18 Years - 75 Years | Suzhou Junjing BioSciences Co., Ltd. | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) | NCT01344707 | Advanced Hemato... | 4SC-202 | 18 Years - | 4SC AG | |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving | NCT01684150 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... | EPZ-5676 | 18 Years - 90 Years | Ipsen | |
| Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies | NCT01034475 | Advanced Hemato... | CPI-613 | 18 Years - | Wake Forest University Health Sciences | |
| Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | NCT00943592 | Advanced Hemato... Leukemia Preleukemia | Clofarabine Melphalan Campath Stem Cell Trans... | 18 Years - 75 Years | University of Chicago | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | NCT02141828 | Leukemia Acute Myeloid L... Acute Lymphocyt... Acute Leukemias | EPZ-5676 | 3 Months - 18 Years | Ipsen | |
| The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer | NCT04991129 | Advanced Hemato... Advanced Solid ... | WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 WJ01024 | 18 Years - 75 Years | Suzhou Junjing BioSciences Co., Ltd. | |
| INCB018424 in Patients With Advanced Hematologic Malignancies | NCT00674479 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Chronic Myeloge... | INCB018424 | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving | NCT01684150 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... | EPZ-5676 | 18 Years - 90 Years | Ipsen | |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | NCT05088356 | Allogeneic Hema... Advanced Hemato... Acute Leukemia Chronic Myeloge... Myelodysplastic... Myeloproliferat... | Purified regula... Fludarabine Melphalan CliniMACS CD34 ... Tacrolimus Cyclophosphamid... Plerixafor Filgrastim gran... Thiotepa Mycophenolate M... Ruxolitinib | 18 Years - 75 Years | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
